Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Gains from Sales and Divestitures: 2015-2020

Historic Gains from Sales and Divestitures for Myriad Genetics (MYGN) over the last 4 years, with Jun 2020 value amounting to $900,000.

  • Myriad Genetics' Gains from Sales and Divestitures rose 12.50% to $900,000 in Q2 2020 from the same period last year, while for Jun 2020 it was $900,000, marking a year-over-year increase of 12.50%. This contributed to the annual value of $900,000 for FY2020, which is 12.50% up from last year.
  • Per Myriad Genetics' latest filing, its Gains from Sales and Divestitures stood at $900,000 for Q2 2020, which was down 0.00% from $900,000 recorded in Q1 2020.
  • In the past 5 years, Myriad Genetics' Gains from Sales and Divestitures ranged from a high of $900,000 in Q4 2019 and a low of $400,000 during Q1 2016.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $800,000 (2019), whereas its average is $814,286.
  • Data for Myriad Genetics' Gains from Sales and Divestitures shows a peak YoY surged of 1,951.28% (in 2016) over the last 5 years.
  • Quarterly analysis of 5 years shows Myriad Genetics' Gains from Sales and Divestitures stood at $400,000 in 2016, then spiked by 75.00% to $700,000 in 2017, then soared by 75.00% to $700,000 in 2018, then increased by 14.29% to $900,000 in 2019, then grew by 12.50% to $900,000 in 2020.
  • Its Gains from Sales and Divestitures was $900,000 in Q2 2020, compared to $900,000 in Q1 2020 and $900,000 in Q4 2019.